<DOC>
	<DOCNO>NCT02064465</DOCNO>
	<brief_summary>This open-label , randomised , parallel-group study demonstrate bioequivalence lamotrigine 100mg two different formulation , dispersible/chewable tablet compress tablet , healthy subject fast condition . Subjects randomize equal number dose either lamotrigine dispersible/chewable ( Test ) 100mg tablet lamotrigine compress ( Reference ) 100mg tablet . Pharmacokinetic blood sample collect 216 hour post dose . Safety ( tolerability ) observe 216 hour post dose . Safety assessment include regular monitoring vital sign , ECG 's , adverse event ( AEs ) safety laboratory test . A follow-up visit schedule within 10-17 day post-dose .</brief_summary>
	<brief_title>The Bioequivalence Study Lamotrigine Dispersible/Chewable Tablets 100mg Compared With Compressed Tablet 100 mg</brief_title>
	<detailed_description>This single dose , open-label , randomize , parallel-group study demonstrate bioequivalence lamotrigine dispersible/chewable tablet lamotrigine compress tablet 100mg healthy Chinese male subject fasting condition . Approximate 138 Chinese healthy male subject enrol accordance inclusion exclusion criterion . Subjects 18 45 year , healthy body mass index 19-24 kg/m2 sign inform consent . Having give write informed consent , subject require undergo pre-study medical screen within 14 day dose day . Subjects admit Day 0 ( day dose ) stay unit 24-hour post-dose assessment Day 2 . The time subject discharge unit may agree unit staff subject must return designate pharmacokinetic ( PK ) sample schedule time observation . The subject randomize equal number dose fast condition either lamotrigine dispersible/chewable tablet lamotrigine compress tablet . The pharmacokinetic assessment last 10 day . The blood sample collect immediately dose ( pre-dose ) 0.5 , 1 , 1.5 , 2 , 2.5 , 3 , 4 , 6 , 8 , 12 , 24 , 36 , 48 , 72 , 96 , 120 , 144 , 168 216 hour post dose determination lamotrigine concentration blood . Safety tolerability evaluation observe 216 hour post-dose , include adverse event , vital sign , physical examination , electrocardiogram . All subject require undergo follow-up assessment within 10-17 day receive study medication .</detailed_description>
	<mesh_term>Lamotrigine</mesh_term>
	<mesh_term>Anticonvulsants</mesh_term>
	<criteria>Healthy Chinese male nonsmoker , base medical history physical examination , age 18 45 year age inclusive , time signing informed consent . Healthy determine responsible experienced physician , base medical evaluation include medical history , physical examination , laboratory test cardiac monitoring . A subject clinical abnormality laboratory parameter ( ) is/are specifically list inclusion exclusion criterion , outside reference range population study may include Investigator ( consultation GlaxoSmithKline ( GSK ) Medical Monitor require ) agree document find unlikely introduce additional risk factor interfere study procedure . Body weight &gt; = 50 kg BMI within range 19 24 kg/m2 ( inclusive ) . Capable return study site followup accord requirement protocol willing comply policy , procedure restriction study . Capable read understand information list consent form . Signing informed consent prior study related procedure . Aspartate transaminase ( AST ) , Alanine transaminase ( ALT ) , alkaline phosphatase ( ALP ) total bilirubin &lt; = 1.5âœ•Upper limit normal ( ULN ) ( total bilirubin &gt; 1.5 x ULN alone acceptable direct bilirubin &lt; 35 % total bilirubin ) . Normal blood pressure ( systolic blood pressure 90140 mmHg , inclusive , diastolic blood pressure &lt; 90mmHg ) pulse rate ( 60100 , inclusive ) . No clinically significant abnormality 12lead ECG . Corrected QT interval ( QTc ) &lt; 450 m ; correct QT interval &lt; 480 ms subject bundlebranch block , base single average QTc value triplicate ECGs obtain brief recording period . Male subject female partner childbearing potential must use one contraceptive method first dose study treatment followup visit . Current chronic history cardiovascular , respiratory , gastrointestinal , endocrine , hematological , psychical nervous system disease , use drug change absorption , metabolism elimination study drug , result danger drug diseases interfere interpretation study data . Current chronic history liver disease , know hepatic biliary abnormality Gilbert 's syndrome ( exception asymptomatic gallstone ) . Current past history nervouspsychiatric disorder , assess Columbia Suicide Severity Rating Scalebaseline evaluation opinion investigator subject risk suicide history suicide behavior/attempt . History regular alcohol consumption within 6 month study define : average weekly intake &gt; 14 drink . One drink equivalent 12 g alcohol : 12 ounce ( 360 ml ) beer , 5 ounce ( 150 ml ) wine 1.5 ounce ( 45 ml ) 80 proof distil spirit . Consumption grapefruit grapefruit juice within 7 day prior first dose study medication . History sensitivity heparin heparininduced thrombocytopenia . History asthma , anaphylaxis anaphylactic reaction , severe allergic response . Subjects receive lamotrigine previously ( subject receive placebo previous study allow ) History sensitivity study medication , component thereof history drug allergy , opinion investigator GSK Medical Monitor , contraindicate participation . Unable refrain use prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St John 's Wort ) within 14 day prior dose day , opinion Principal Investigator , may interfere study procedure compromise safety . A positive Hepatitis B surface antigen ( HBsAg ) positive Hepatitis C antibody ( HCAb ) result screen A positive prestudy drug/alcohol screen . A positive test HIV antibody screening . Where participation study would result donation blood blood product excess 500 mL within 56 day period . The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . Exposure four new chemical entity within 12 month prior first dose day . Unwillingness inability follow procedure outline protocol .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>